A Potential Drug Target: CDC42EP3, a Characterization of a CD42-Expressing Protein in Cancer

A Potential Drug Target: CDC42EP3, a Characterization of a CD42-Expressing Protein in Cancer

Introduction

Cancer is a leading cause of morbidity and mortality worldwide, and efforts to develop new therapeutic approaches to treat this disease have been ongoing for decades. One of the promising strategies in the fight against cancer is the identification of potential drug targets, which can be used to inhibit the growth and proliferation of cancer cells. In this article, we focus on CDC42EP3, a protein that has been identified as a potential drug target in cancer.

CDC42EP3: Structure and Function

CDC42EP3, also known as CDC42-EP3, is a protein that is expressed in various tissues, including the brain, heart, liver, and gastrointestinal tract. It is a 21-kDa transmembrane protein that is composed of four distinct domains: an N- terminus, a T-terminus, a middle domain, and an C-terminus. The N-terminus of CDC42EP3 is rich in amino acids that are involved in the formation of a hydrophobic core, which is known to enhance the protein's stability and localization to the cell membrane. The T-terminus of the protein contains a unique farnesylated cysteine ??????residue, which is known to play a critical role in the regulation of protein stability and localization. The middle domain of CDC42EP3 contains a series of amino acids that are involved in the formation of a hydrophilic tail, which is known to enhance the protein's stability and localization to the intracellular cytoplasm. The C-terminus of the protein contains a series of amino acids that are involved in the formation of a hydrophobic tail, which is known to enhance the protein's stability and localization to the intracellular cytoplasm.

CDC42EP3 is a unique protein that is expressed in various tissues and is involved in the regulation of protein stability and localization. Its unique farnesylated cysteine ??????residue and hydrophilic tail domains make it an attractive candidate for drug targeting.

CDC42EP3 as a Drug Target

CDC42EP3 has been identified as a potential drug target due to its unique structure and function. One of the main reasons for its potential as a drug target is its involvement in the regulation of protein stability and localization. Studies have shown that CDC42EP3 can interact with various protein substrates, including the protein p120GAP. This interaction suggests that CDC42EP3 may play a role in the regulation of protein stability and localization, and that it may be a useful target for drug development.

Another reason for its potential as a drug target is its unique expression pattern. Studies have shown that CDC42EP3 is expressed in various tissues, including the brain, heart, liver, and gastrointestinal tract. This makes it an attractive candidate for drug targeting, as it suggests that a drug developed for one tissue may not have any effect on the others.

In addition, the fact that CDC42EP3 is a 21-kDa protein also suggests that it may be a small molecule that can be easily administered to patients. This is important, as many drugs used in current cancer treatments are large molecules that have a high risk of side effects.

Conclusion

In conclusion, CDC42EP3 is a unique protein that has been identified as a potential drug target due to its involvement in the regulation of protein stability and localization, its unique expression pattern, and the fact that it is a 21-kDa protein. Further studies are needed to determine its full potential as a drug target and to develop safe and effective drugs that can be used to inhibit its activity.

Protein Name: CDC42 Effector Protein 3

Functions: Probably involved in the organization of the actin cytoskeleton. May act downstream of CDC42 to induce actin filament assembly leading to cell shape changes. Induces pseudopodia formation in fibroblasts

The "CDC42EP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC42EP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B